Cancer Res Treat.  2023 Jan;55(1):1-4. 10.4143/crt.2023.265.

Oligometastasis: More Lessons to Be Learned

• Kim KH
• Ahn YC
• Oligometastasis Working Group, Korea Cancer Association

• KMID: 2537986
• DOI: http://doi.org/10.4143/crt.2023.265

Reference

References

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13:8–10.

2. Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kim KH, et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat. 2022; 54:953–69.

3. Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022; 19:585–99.

4. Tan VS, Palma DA. Top ten lessons learned from trials in oligometastatic cancers. Cancer Res Treat. 2023; 55:5–14.

5. National Comprehensive Cancer Network. Central nervous system cancers (version 2. 2022) [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network;2022. [cited 2023 Jan 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf .

6. Ashram S, Bahig H, Barry A, Blanchette D, Celinksi A, Chung P, et al. Planning trade-offs for SABR in patients with 4 to 10 metastases: a substudy of the SABR-COMET-10 randomized trial. Int J Radiat Oncol Biol Phys. 2022; 114:1011–5.

7. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020; 38:2830–8.

8. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018; 4:e173501.

9. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019; 37:1558–65.

10. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018; 24:4960–7.

11. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545:60–5.

12. Kim J, Chang JS, Sung W, Kim JS, Kim TH, Choi SH, et al. A comparison of 2 disease burden assessment methods (3d volume versus the number of lesions) for prognostication of survival in metastatic melanoma: implications for the characterization of oligometastatic disease. Int J Radiat Oncol Biol Phys. 2022; 114:883–91.

13. Willmann J, Vlaskou Badra E, Adilovic S, Christ SM, Ahmadsei M, Mayinger M, et al. Distant metastasis velocity as a novel prognostic score for overall survival after disease progression following stereotactic body radiation therapy for oligometastatic disease. Int J Radiat Oncol Biol Phys. 2022; 114:871–82.

14. Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys. 2022; 114:611–6.

15. Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. 2022. Jan. 30. [Epub]. https://doi.org/10.1093/jnci/djac015 .

16. Kim KH, Yoon S, Ahn HK, Lee SY, Lee GW, Lee SS, et al. A multicenter two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancer (ABLATE, KCSG-LU21-11). Clin Lung Cancer. 2022; 23:e536–9.

17. Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, et al. UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol (R Coll Radiol). 2022; 34:288–300.

18. Lee DH. Treating oligometastses, prelude or just hassles of systemic treatment. Cancer Res Treat. 2022; 54:951–2.

19. McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021; 39:30–7.

20. Theelen WS, Peulen HM, Lalezari F, van der Noort V, de Vries JF, Aerts JG, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019; 5:1276–82.

21. Corkum MT, Fakir H, Palma DA, Nguyen T, Bauman GS. Can polymetastatic disease be ARRESTed using SABR? A dosimetric feasibility study to inform development of a phase 1 trial. Adv Radiat Oncol. 2021; 6:100734.

22. Grimm J, Marks LB, Jackson A, Kavanagh BD, Xue J, Yorke E. High dose per fraction, hypofractionated treatment effects in the clinic (HyTEC): an overview. Int J Radiat Oncol Biol Phys. 2021; 110:1–10.

23. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21:e18–28.

24. Baker S, Mou B, Jiang W, Liu M, Bergman AM, Schellenberg D, et al. Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022; 114:849–55.

25. Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022; 168:256–64.